Features | Partner Sites | Information | LinkXpress
Sign In

Clostridium difficile Assay Receives FDA Clearance

By Labmedica International staff writers
Posted on 28 Nov 2013
Image: Micrograph of Clostridium difficile made from an impression smear of 72-hour growth on anaerobe blood agar (Photo courtesy of Dr. Gilda Jones).
Image: Micrograph of Clostridium difficile made from an impression smear of 72-hour growth on anaerobe blood agar (Photo courtesy of Dr. Gilda Jones).
An assay which detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile has received official clearance.

The assay, manufactured by IntelligentMDx (Waltham, MA, USA) can detect C. difficile in human liquid or soft stool specimens collected from patients suspected of having Clostridium difficile-associated disease.

The assay is called IMDx C. difficile and is designed for use with Abbott m2000 Real Time system (Abbott Molecular; Abbott Park, IL, USA). This is the third test from IMDx to receive US Food and Drug Administration (FDA; Silver Springs, MD, USA) clearance within three months for use on Abbott’s fully automated m2000 system and follows clearances of the IMDx VanR for Abbott m2000 and IMDx Flu A/B and RSV for Abbott m2000 assays.

Analytical reactivity studies demonstrated that the IMDx C. difficile for Abbott m2000 assay is capable of detecting the 31 different toxigenic C. difficile strains that were tested. These strains represent the global diversity of C. difficile strains, including nucleosome assembly protein I (NAP1), and toxin B (tcdB)-variant strains, such as 1470. The IMDx C. difficile for Abbott m2000 assay is part of a broad real-time polymerase chain reaction PCR test menu designed, developed, and manufactured for use on Abbott’s RealTime m2000 system under a multi-year distribution agreement with Abbott.

Effective molecular diagnostic tests for early detection of C. difficile remain critical to help control the spread of infection and the threat of more serious complications. C. difficile is the leading cause of hospital-acquired diarrhea and may cause more severe intestinal conditions such as pseudomembranous colitis. According to the US Centers of Disease Control and Prevention (CDC; Atlanta, GA, USA) C. difficile infection is linked to approximately 14,000 deaths in the USA annually.

Alice Jacobs Nesselrodt, MD, Chairman and CEO of IMDx, said, “FDA clearance of the IMDx C. difficile for Abbott m2000 assay comes at a pivotal time when incidence of C. difficile infection and severity in both hospital and community settings is increasing. Detection of a wide variety of C. difficile strains, including hypervirulent strains, by the IMDx C. difficile for Abbott m2000 assay will help ensure that a high number of cases of C. difficile are detected in a timely manner, regardless of the source of infection.”

Related Links:

Abbott Molecular 
US Centers of Disease Control and Prevention



Genetic Tests

view channel
Image: The QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen)

Blood Tests Predict Risk of Sudden Cardiac Death

A simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).... Read more


view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more


view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.